Comparative Effect Of Curcumin Versus Liposomal Curcumin On Systemic Pro-Inflammatory Cytokines Profile, MCP-1 And RANTES In Experimental Diabetes Mellitus

References

• Sandur SK, Pandey MK, Sung B, et al. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis. 2007;28(8):1765–1773. doi:10.1093/carcin/bgm12317522064
   PubMed Web of Science ®Google Scholar
• Mehta J, Rayalam S, Wang X. Cytoprotective effects of natural compounds against oxidative stress. Antioxidants (Basel). 2018;7(10):E147. doi:10.3390/antiox710014730347819
   PubMedGoogle Scholar
• Attiq A, Jalil J, Husain K, et al. Raging the war against inflammation with natural products. Front Pharmacol. 2018;9:976.30245627
   PubMed Web of Science ®Google Scholar
• Shimizu K, Funamoto M, Sunagawa Y, et al. Anti-inflammatory action of curcumin and its use in the treatment of lifestyle-related diseases. Eur Cardiol. 2019;14(2):117–122. doi:10.15420/ecr.2019.17.231360234
   PubMed Web of Science ®Google Scholar
• Kunnumakkara AB, Bordoloi D, Padmavathi G, et al. Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. Br J Pharmacol. 2017;174(11):1325–1348. doi:10.1111/bph.v174.1127638428
   PubMed Web of Science ®Google Scholar
• Teiten MH, Dicato M, Diederich M. Hybrid curcumin compounds: a new strategy for cancer treatment. Molecules. 2014;19(12):20839–20863. doi:10.3390/molecules19122083925514225
   PubMed Web of Science ®Google Scholar
• Kesharwani SS, Ahmad R, Bakkari MA, et al. Site-directed non-covalent polymer-drug complexes for inflammatory bowel disease (IBD): formulation development, characterization and pharmacological evaluation. J Control Release. 2018;290:165–179. doi:10.1016/j.jconrel.2018.08.00430142410
   PubMed Web of Science ®Google Scholar
• Boarescu PM, Chirilă I, Bulboacă AE, et al. Effects of curcumin nanoparticles in isoproterenol-induced myocardial infarction. Oxid Med Cell Longev. 2019;2019:Article ID 7847142. doi:10.1155/2019/7847142
   Web of Science ®Google Scholar
• Boarescu PM, Boarescu I, Bocșan IC, et al. Curcumin nanoparticles protect against isoproterenol induced myocardial infarction by alleviating myocardial tissue oxidative stress, electrocardiogram, and biological changes. Molecules. 2019;24(15):E2802. doi:10.3390/molecules2415280231374848
   PubMedGoogle Scholar
• Bulboacă AE, Porfire AS, Tefas LR, et al. Liposomal curcumin is better than curcumin to alleviate complications in experimental diabetic mellitus. Molecules. 2019;24(5):846. doi:10.3390/molecules24050846
   PubMed Web of Science ®Google Scholar
• Ganugula R, Arora M, Jaisamut P, et al. Nano-curcumin safely prevents streptozotocin-induced inflammation and apoptosis in pancreatic beta cells for effective management of Type 1 diabetes mellitus. Br J Pharmacol. 2017;174(13):2074–2084. doi:10.1111/bph.1381628409821
   PubMed Web of Science ®Google Scholar
• Kumar S, Kesharwani SS, Mathur H, et al. Molecular complexation of curcumin with pH sensitive cationic copolymer enhances the aqueous solubility, stability and bioavailability of curcumin. Eur J Pharm Sci. 2016;82:86–96. doi:10.1016/j.ejps.2015.11.01026588875
   PubMed Web of Science ®Google Scholar
• Lopresti AL. The problem of curcumin and its bioavailability: could its gastrointestinal influence contribute to its overall health-enhancing effects? Adv Nutr. 2018;9(1):41–50. doi:10.1093/advances/nmx01129438458
   PubMed Web of Science ®Google Scholar
• Feng T, Wei Y, Lee RJ, et al. Liposomal curcumin and its application in cancer. Int J Nanomedicine. 2017;12:6027–6044. doi:10.2147/IJN28860764
   PubMed Web of Science ®Google Scholar
• Raimondo S, Giavaresi G, Lorico A, et al. Extracellular vesicles as biological shuttles for targeted therapies. Int J Mol Sci. 2019;20(8):E1848. doi:10.3390/ijms2008184830991632
   PubMedGoogle Scholar
• Schiborr C, Eckert GP, Rimbach G, et al. A validated method for the quantification of curcumin in plasma and brain tissue by fast narrow-bore high-performance liquid chromatography with fluorescence detection. Anal Bioanal Chem. 2010;397(5):1917–1925. doi:10.1007/s00216-010-3719-320419505
   PubMed Web of Science ®Google Scholar
• Liliemark E, Liliemark J, Kållberg N, et al. Studies of the organ distribution in mice of teniposide liposomes designed for treatment of diseases in the mononuclear phagocytic system. Pediatr Res. 1995;38(1):7–10. doi:10.1203/00006450-199507000-000027478800
   PubMedGoogle Scholar
• Elguindy NM, Awad D, Zaky A, et al. Liposomal curcumin improves insulin resistance in type 2 diabetic rats by upregulating hepatic GLUT-2. J Diabetes Metab. 2017;8:8.
   Google Scholar
• Padgett LE, Broniowska KA, Hansen PA, et al. The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis. Ann N Y Acad Sci. 2013;1281:16–35. doi:10.1111/j.1749-6632.2012.06826.x23323860
   PubMed Web of Science ®Google Scholar
• Willcox A, Gillespie KM. Histology of type 1 diabetes pancreas. Methods Mol Biol. 2016;1433:105–117.26801316
   PubMedGoogle Scholar
• Morgan NG, Richardson SJ. Fifty years of pancreatic islet pathology in human type 1 diabetes: insights gained and progress made. Diabetologia. 2018;61(12):2499–2506. doi:10.1007/s00125-018-4731-y30255378
   PubMedGoogle Scholar
• Zhang JM, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin. 2007;45(2):27–37. doi:10.1097/AIA.0b013e318034194e17426506
   PubMedGoogle Scholar
• Qu D, Liu J, Lau CW, et al. IL-6 in diabetes and cardiovascular complications. Br J Pharmacol. 2014;171(15):3595–3603. doi:10.1111/bph.1271324697653
   PubMed Web of Science ®Google Scholar
• Panee J. Monocyte chemoattractant protein 1 (MCP-1) in obesity and diabetes. Cytokine. 2012;60(1):1–12. doi:10.1016/j.cyto.2012.06.01822766373
   PubMed Web of Science ®Google Scholar
• Mora C, Navarro JF. Inflammation and diabetic nephropathy. Curr Diab Rep. 2006;6(6):463–468. doi:10.1007/s11892-006-0080-117118230
   PubMedGoogle Scholar
• Navarro-Gonzalez JF, Jarque A, Muros M, et al. Tumor necrosis factor-alpha as a therapeutic target for diabetic nephropathy. Cytokine Growth Factor Rev. 2009;20(2):165–173. doi:10.1016/j.cytogfr.2009.02.00519251467
   PubMed Web of Science ®Google Scholar
• Qiao YC, Chen YL, Pan YH, et al. The change of serum tumor necrosis factor alpha in patients with type 1 diabetes mellitus: a systematic review and meta-analysis. PLoS One. 2017;12(4):e0176157. doi:10.1371/journal.pone.017615728426801
   PubMedGoogle Scholar
• Koj A. Initiation of acute phase response and synthesis of cytokines. Biochim Biophys Acta. 1996;1317(2):84–94. doi:10.1016/S0925-4439(96)00048-88950192
   PubMedGoogle Scholar
• Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes. 2005;54(Suppl 2):S114–124. doi:10.2337/diabetes.54.suppl_2.S11416306329
   PubMed Web of Science ®Google Scholar
• Jain SK, Rains J, Croad J, et al. Curcumin supplementation lowers TNF-alpha, IL-6, IL-8, and MCP-1 secretion in high glucose-treated cultured monocytes and blood levels of TNF-alpha, IL-6, MCP-1, glucose, and glycosylated hemoglobin in diabetic rats. Antioxid Redox Signal. 2009;11:241–249. doi:10.1089/ars.2008.214018976114
   PubMed Web of Science ®Google Scholar
• Kolattukudy PE, Niu J. Inflammation, endoplasmic reticulum stress, autophagy, and the monocyte chemoattractant protein-1/CCR2 pathway. Circ Res. 2012;110(1):174–189. doi:10.1161/CIRCRESAHA.111.24321222223213
   PubMedGoogle Scholar
• Sarkar SA, Lee CE, Victorino F, et al. Expression and regulation of chemokines in murine and human type 1 diabetes. Diabetes. 2012;61(2):436–446. doi:10.2337/db11-085322210319
   PubMedGoogle Scholar
• Scarim AL, Heitmeier MR, Corbett JA. Irreversible inhibition of metabolic function and islet destruction after a 36 hr exposure to interleukin-1beta. Endocrinology. 1997;138:5301–5307. doi:10.1210/endo.138.12.55839389514
   PubMed Web of Science ®Google Scholar
• Hughes KJ, Chambers KT, Meares GP, et al. Nitric oxides mediates a shift from early necrosis to late apoptosis in cytokine-treated beta-cells that is associated with irreversible DNA damage. Am J Physiol Endocrinol Metabol. 2009;297:E1187–E1196. doi:10.1152/ajpendo.00214.2009
   PubMed Web of Science ®Google Scholar
• Reddy S, Wu D, Elliott RB. Low doses streptozotocin causes diabetes in severe combined immunodeficient (SCID) mice without immune cell infiltration of the pancreatic islets. Autoimmunity. 1995;20(2):83–92. doi:10.3109/089169395090019317578872
   PubMed Web of Science ®Google Scholar
• Bulboacă A, Bolboacă SD, Suci S. Protective effect of curcumin in fructose-induced metabolic syndrome and in streptozotocin-induced diabetes in rats. Iran J Basic Med Sci. 2016;19(6):585–593.27482338
   PubMed Web of Science ®Google Scholar
• Tefas LR, Sylvester B, Tomuta I, et al. Development of antiproliferative long-circulating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach. Drug Des Devel Ther. 2017;11:1605–1621. doi:10.2147/DDDT
   PubMed Web of Science ®Google Scholar
• Bulboacă AE, Bolboacă SD, Stănescu IC, et al. The effect of intravenous administration of liposomal curcumin in addition to sumatriptan treatment in an experimental migraine model in rats. Int J Nanomedicine. 2018;13:3093–3103. doi:10.2147/IJN29872296
   PubMed Web of Science ®Google Scholar
• King AJ. The use of animal models in diabetes research. Br J Pharmacol. 2012;166(3):877–894. doi:10.1111/j.1476-5381.2012.01911.x22352879
   PubMed Web of Science ®Google Scholar
• Elbialy NS, Aboushoushah SF, Alshammari WW. Long-term biodistribution and toxicity of curcumin capped iron oxide nanoparticles after single-dose administration in mice. Life Sci. 2019;230:76–83. doi:10.1016/j.lfs.2019.05.04831128136
   PubMedGoogle Scholar
• Shahani K, Swaminathan SK, Freeman D, et al. Injectable sustained release microparticles of curcumin: a new concept for cancer chemoprevention. Cancer Res. 2010;70(11):4443–4452. doi:10.1158/0008-5472.CAN-09-436220460537
   PubMed Web of Science ®Google Scholar
• Anchi P, Khurana A, Swain D, et al. Dramatic improvement in pharmacokinetic and pharmacodynamic effects of sustain release curcumin microparticles demonstrated in experimental type 1 diabetes model. Eur J Pharm Sci. 2019;130:200–214. doi:10.1016/j.ejps.2019.02.00230731237
   PubMed Web of Science ®Google Scholar
• Melo A, Leite-Almeida H, Ferreira C, et al. Exposure to ketamine anesthesia affects rat impulsive behavior. Front Behav Neurosci. 2016;10:226. doi:10.3389/fnbeh.2016.0022627932959
   PubMedGoogle Scholar
• Nordquist L, Johansson M. Proinsulin C-peptide: friend or foe in the development of diabetes-associated complications? Vasc Health Risk Manag. 2008;4(6):1283–1288. doi:10.2147/VHRM.S395519337542
   PubMedGoogle Scholar
• Rubenstein AH, Kuzuya H, Horwitz DL. Clinical significance of circulating C-peptide in diabetes mellitus and hypoglycemic disorders. Arch Intern Med. 1977;137(5):625–632. doi:10.1001/archinte.1977.03630170047014193451
   PubMedGoogle Scholar
• Bonser AM, Garcia-Webb P. C-peptide measurement: methods and clinical utility. Crit Rev Clin Lab Sci. 1984;19(4):297–352. doi:10.3109/104083684091657666373142
   PubMedGoogle Scholar
• Yosten GLC, Maric-Bilkan C, Luppi P, et al. Physiological effects and therapeutic potential of proinsulin C-peptide. Am J Physiol Endocrinol Metab. 2014;307:E955–E968. doi:10.1152/ajpendo.00130.201425249503
   PubMed Web of Science ®Google Scholar
• Kitabchi AE. Proinsulin and C-peptide: a review. Metabolism. 1977;26(5):547–587. doi:10.1016/0026-0495(77)90099-3403392
   PubMedGoogle Scholar
• Leyva-García E, Lara-Martínez R, Morán-Zanabria L, et al. Novel insight into streptozotocin-induced diabetic rats from the protein misfolding perspective. Sci Rep. 2017;7(1):11552. doi:10.1038/s41598-017-11776-y28912603
   PubMedGoogle Scholar
• Wójcikowski C, Maier V, Dominiak K, et al. Effects of synthetic rat C-peptide in normal and diabetic rats. Diabetologia. 1983;25:288–290. doi:10.1007/BF002799456139319
   PubMedGoogle Scholar
• Sato Y, Oshida Y, Han YQ, et al. C-peptide fragments stimulate glucose utilization in diabetic rats. Cell Mol Life Sci. 2004;61:727–732. doi:10.1007/s00018-003-3460-615052415
   PubMedGoogle Scholar
• Wu W, Oshida Y, Yang WP, et al. Effect of C-peptide administration on whole body glucose utilization in STZ-induced diabetic rats. Acta Physiol Scand. 1996;157:253–258. doi:10.1046/j.1365-201X.1996.489236000.x8800366
   PubMedGoogle Scholar
• Johansson BL, Linde B, Wahren J. Effects of C-peptide on blood flow, capillary diffusion capacity and glucose utilization in the exercising forearm of type 1 (insulin-dependent) diabetic patients. Diabetologia. 1992;35:1151–1158. doi:10.1007/BF004013691478367
   PubMedGoogle Scholar
• Ghorbani A, Omrani GR, Hadjzadeh MA, Varedi M. Proinsulin C-peptide inhibits lipolysis in diabetic rat adipose tissue through phosphodiesterase-3B enzyme. Horm Metab Res. 2013;45:221–225. doi:10.1055/s-0032-132376422990990
   PubMedGoogle Scholar
• Yu SS, Kitbachi AE. Biological activity of proinsulin and related polypeptides in the fat tissue. J Biol Chem. 1973;248:3753–3761.4708090
   PubMed Web of Science ®Google Scholar
• Wallerath T, Kunt T, Forst T, et al. Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide. Nitric Oxide. 2003;9:95–102. doi:10.1016/j.niox.2003.08.00414623175
   PubMed Web of Science ®Google Scholar
• Sjöberg S, Gunnarsson R, Gjötterberg M, et al. Residual insulin production, glycaemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1987;30:208–213. doi:10.1007/BF002704173297896
   PubMed Web of Science ®Google Scholar
• Rebsomen L, Pitel S, Boubred F, et al. C-peptide replacement improves weight gain and renal function in diabetic rats. Diabetes Metab. 2006;32:223–228. doi:10.1016/S1262-3636(07)70272-016799398
   PubMedGoogle Scholar
• Klein R, Moss SE, Klein BE, et al. Wisconsin Epidemiologic Study of Diabetic Retinopathy. XII. Relationship of C-peptide and diabetic retinopathy. Diabetes. 1990;39(11):1445–1450. doi:10.2337/diab.39.11.14452121570
   PubMedGoogle Scholar
• Kuo JZ, Guo X, Klein R, et al. Association of fasting insulin and C peptide with diabetic retinopathy in Latinos with type 2 diabetes. BMJ Open Diabetes Res Care. 2014;2(1):e000027. doi:10.1136/bmjdrc-2014-000027
   PubMedGoogle Scholar
• Al-Rasheed NM, Willars GB, Brunskill NJ. C-peptide signals via Galpha i to protect against TNF-alpha-mediated apoptosis of opossum kidney proximal tubular cells. J Am Soc Nephrol. 2006;17:986–995. doi:10.1681/ASN.200508079716510765
   PubMedGoogle Scholar
• Maezawa Y, Yokote K, Sonezaki K, et al. Influence of C-peptide on early glomerular changes in diabetic mice. Diabetes Metab Res Rev. 2006;22:313–322. doi:10.1002/(ISSN)1520-756016389646
   PubMedGoogle Scholar
• Sima AA, Zhang W, Sugimoto K, et al. C-peptide prevents and improves chronic type I diabetic polyneuropathy in the BB/Wor rat. Diabetologia. 2001;44:889–897. doi:10.1007/s00125010057011508275
   PubMed Web of Science ®Google Scholar
• Sima AA, Li ZG. The effect of C-peptide on cognitive dysfunction and hippocampal apoptosis in type 1 diabetic rats. Diabetes. 2005;54:1497–1505. doi:10.2337/diabetes.54.5.149715855338
   PubMedGoogle Scholar
• Ghorbani A, Shafiee-Nick R. Pathological consequences of C-peptide deficiency in insulin-dependent diabetes mellitus. World J Diabetes. 2015;6(1):145–150. doi:10.4239/wjd.v6.i1.14525685285
   PubMedGoogle Scholar
• Scalia R, Coyle KM, Levine BJ, et al. C-peptide inhibits leukocyte-endothelium interaction in the microcirculation during acute endothelial dysfunction. Faseb J. 2000;14:2357–2364. doi:10.1096/fj.00-0183com11053258
   PubMed Web of Science ®Google Scholar
• Fatima N, Faisal SM, Zubair S, et al. Role of pro-inflammatory cytokines and biochemical markers in the pathogenesis of type 1 diabetes: correlation with age and glycemic condition in diabetic human subjects. PLoS One. 2016;11(8):e0161548. doi:10.1371/journal.pone.016154827575603
   PubMed Web of Science ®Google Scholar
• Hoeldtke RD, Bryner KD, McNeill DR, et al. Oxidative stress and insulin requirements in patients with recent-onset type 1 diabetes. J Clin Endocrinol Metab. 2003;88:1624–1628. doi:10.1210/jc.2002-02152512679448
   PubMed Web of Science ®Google Scholar
• Teodoro JS, Gomes AP, Varela AT, et al. Uncovering the beginning of diabetes: the cellular redox status and oxidative stress as starting players in hyperglycemic damage. Mol Cell Biochem. 2013;376:103–110. doi:10.1007/s11010-012-1555-923292031
   PubMedGoogle Scholar
• Griffiths HR, Gao D, Pararasa C. Redox regulation in metabolic programming and inflammation. Redox Biol. 2017;12:50–57. doi:10.1016/j.redox.2017.01.02328212523
   PubMed Web of Science ®Google Scholar
• Espinoza-Jiménez A, Peón AN, Terrazas LI. Alternatively activated macrophages in types 1 and 2 diabetes. Mediators Inflamm. 2012;2012:815953. doi:10.1155/2012/81595323326021
   PubMedGoogle Scholar
• Rabinovitch A, Suarez-Pinzon WL. Cytokines and their roles in pancreatic islet β-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol. 1998;55(8):1139–1149. doi:10.1016/S0006-2952(97)00492-99719467
   PubMed Web of Science ®Google Scholar
• Kim SS, Jang HJ, Oh MY, et al. Tetrahydrocurcumin enhances islet cell function and attenuates apoptosis in mouse islets. Transplant Proc. 2018;50(9):2847–2853. doi:10.1016/j.transproceed.2018.03.03330401410
   PubMedGoogle Scholar
• Panahi Y, Khalili N, Sahebi E, et al. Curcuminoids plus piperine modulate adipokines in type 2 diabetes mellitus. Curr Clin Pharmacol. 2017;12(4):253–258. doi:10.2174/157488471366618010409564129299989
   PubMed Web of Science ®Google Scholar
• Daugherty DJ, Marquez A, Calcutt NA, et al. A novel curcumin derivative for the treatment of diabetic neuropathy. Neuropharmacology. 2018;129:26–35. doi:10.1016/j.neuropharm.2017.11.00729122628
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang Y, Liu DB, et al. Curcumin attenuates diabetic neuropathic pain by downregulating TNF-α in a rat model. Int J Med Sci. 2013;10(4):377–381. doi:10.7150/ijms.522423471081
   PubMed Web of Science ®Google Scholar
• Devadasu VR, Wadsworth RM, Kumar MN. Protective effects of nanoparticulate coenzyme Q10 and curcumin on inflammatory markers and lipid metabolism in streptozotocin-induced diabetic rats: a possible remedy to diabetic complications. Drug Deliv Transl Res. 2011;1(6):448–455. doi:10.1007/s13346-011-0041-325786365
   PubMedGoogle Scholar
• Martin AP, Rankin S, Pitchford S, et al. Increased expression of CCL2 in insulin-producing cells of transgenic mice promotes mobilization of myeloid cells from the bone marrow, marked insulitis, and diabetes. Diabetes. 2008;57(11):3025–3033. doi:10.2337/db08-062518633103
   PubMedGoogle Scholar
• Deshmane SL, Kremlev S, Amini S, et al. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29(6):313–326. doi:10.1089/jir.2008.002719441883
   PubMed Web of Science ®Google Scholar
• Cvetkovic I, Al-Abed Y, Miljkovic D, et al. Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology. 2005;146(7):2942–2951. doi:10.1210/en.2004-139315790730
   PubMedGoogle Scholar
• Cnop M, Welsh N, Jonas JC, et al. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes. 2005;54(Suppl 2):S97–107. doi:10.2337/diabetes.54.suppl_2.S9716306347
   PubMed Web of Science ®Google Scholar
• Pavan AR, Silva GD, Jornada DH, et al. Unraveling the anticancer effect of curcumin and resveratrol. Nutrients. 2016;8(11):E628. doi:10.3390/nu811062827834913
   PubMed Web of Science ®Google Scholar
• Marshall HE, Merchant K, Stamler JS. Nitrosation and oxidation in the regulation of gene expression. Faseb J. 2000;14(13):1889–1900. doi:10.1096/fj.00.011rev11023973
   PubMed Web of Science ®Google Scholar
• Mlynarski WM, Placha GP, Wolkow PP, et al. Risk of diabetic nephropathy in type 1 diabetes is associated with functional polymorphisms in RANTES receptor gene (CCR5): a sex-specific effect. Diabetes. 2005;54(11):3331–3335. doi:10.2337/diabetes.54.11.333116249462
   PubMedGoogle Scholar
• Somoza N, Vargas F, Roura-Mir C, et al. Pancreas in recent onset insulin-dependent diabetes mellitus. Changes in HLA, adhesion molecules and autoantigens, restricted T cell receptor V beta usage, and cytokine profile. J Immunol. 1994;153(3):1360–1377.7913115
   PubMed Web of Science ®Google Scholar
• Morgan NG, Leete P, Foulis AK, Richardson SJ. Islet inflammation in human type 1 diabetes mellitus. IUBMB Life. 2014;66(11):723–734. doi:10.1002/iub.v66.1125504835
   PubMed Web of Science ®Google Scholar
• Willcox A, Richardson SJ, Bone AJ, et al. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol. 2009;155(2):173–181. doi:10.1111/cei.2009.155.issue-219128359
   PubMedGoogle Scholar
• Jörns A, Günther A, Hedrich HJ, et al. Immune cell infiltration, cytokine expression, and beta-cell apoptosis during the development of type 1 diabetes in the spontaneously diabetic LEW.1AR1/Ztm-IDDM rat. Diabetes. 2005;54(7):2041–2052. doi:10.2337/diabetes.54.7.204115983205
   PubMed Web of Science ®Google Scholar
• Dirice E, Kahraman S, Jiang W, et al. Soluble factors secreted by T cells promote β-cell proliferation. Diabetes. 2014;63(1):188–202. doi:10.2337/db13-020424089508
   PubMed Web of Science ®Google Scholar